⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIRM News
Mirum Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
MIRM
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
businesswire.com
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
MIRM
Egetis Appoints Tiago Nunes as Chief Medical Officer
accessnewswire.com
MIRM
Form 8-K/A
sec.gov
MIRM
NorthSea Therapeutics Bolsters Board, as Orziloben Moves into Late-stage Development
globenewswire.com
MIRM
ALGN
JNJ
GILD
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
businesswire.com
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
MIRM
Form 8-K
sec.gov
MIRM